Dr Reddy's Laboratories (Dr Reddy's Laboratories) EV-to-EBIT : 13.81 (As of Apr. 28, 2024)

View and export this data going back to 2001. Start your Free Trial

What is Dr Reddy's Laboratories EV-to-EBIT?

EV-to-EBIT is calculated as Enterprise Value divided by its EBIT. As of today, Dr Reddy's Laboratories's Enterprise Value is $11,785 Mil. Dr Reddy's Laboratories's EBIT for the trailing twelve months (TTM) ended in Dec. 2023 was $853 Mil. Therefore, Dr Reddy's Laboratories's EV-to-EBIT for today is 13.81.

The historical rank and industry rank for Dr Reddy's Laboratories's EV-to-EBIT or its related term are showing as below:

RDY' s EV-to-EBIT Range Over the Past 10 Years
Min: 11.04 Med: 20.49 Max: 46.21
Current: 14.01

During the past 13 years, the highest EV-to-EBIT of Dr Reddy's Laboratories was 46.21. The lowest was 11.04. And the median was 20.49.

RDY's EV-to-EBIT is ranked better than
60.63% of 668 companies
in the Drug Manufacturers industry
Industry Median: 17.12 vs RDY: 14.01

Joel Greenblatt calls the inversion of this ratio Earnings Yield (Joel Greenblatt) %. Dr Reddy's Laboratories's Enterprise Value for the quarter that ended in Dec. 2023 was $10,955 Mil. Dr Reddy's Laboratories's EBIT for the trailing twelve months (TTM) ended in Dec. 2023 was $853 Mil. Dr Reddy's Laboratories's Earnings Yield (Joel Greenblatt) % for the quarter that ended in Dec. 2023 was 7.79%.

Dr Reddy's Laboratories EV-to-EBIT Historical Data

The historical data trend for Dr Reddy's Laboratories's EV-to-EBIT can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Dr Reddy's Laboratories EV-to-EBIT Chart

Dr Reddy's Laboratories Annual Data

Trend

Mar14

Mar15

Mar16

Mar17

Mar18

Mar19

Mar20

Mar21

Mar22

Mar23

EV-to-EBIT

Get a 7-Day Free Trial

20.30

26.98

27.17

21.17

11.64

Dr Reddy's Laboratories Quarterly Data
	Mar19	Jun19	Sep19	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23
EV-to-EBIT	Get a 7-Day Free Trial															11.75	11.64	12.35	12.75	12.93

Competitive Comparison of Dr Reddy's Laboratories's EV-to-EBIT

For the Drug Manufacturers - Specialty & Generic subindustry, Dr Reddy's Laboratories's EV-to-EBIT, along with its competitors' market caps and EV-to-EBIT data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Dr Reddy's Laboratories's EV-to-EBIT Distribution in the Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, Dr Reddy's Laboratories's EV-to-EBIT distribution charts can be found below:

* The bar in red indicates where Dr Reddy's Laboratories's EV-to-EBIT falls into.

Dr Reddy's Laboratories EV-to-EBIT Calculation

Dr Reddy's Laboratories's EV-to-EBIT for today is calculated as:

EV-to-EBIT	=	Enterprise Value (Today)	/	EBIT (TTM)
	=	11784.642	/	853.09
	=	13.81

Dr Reddy's Laboratories's current Enterprise Value is $11,785 Mil.
Dr Reddy's Laboratories's EBIT for the trailing twelve months (TTM) ended in Dec. 2023 adds up the quarterly data reported by the company within the most recent 12 months, which was $853 Mil.

Dr Reddy's Laboratories (NYSE:RDY) EV-to-EBIT Explanation

This is a more accurate valuation of companies' operation because it considers the debt and cash on its balance sheet, and non-operating items such as interest payment, tax, and one-time items are not included in the Operating Income.

Joel Greenblatt calls the inversion of this ratio Earnings Yield (Joel Greenblatt) %.

Dr Reddy's Laboratories's Earnings Yield (Joel Greenblatt) % for the quarter that ended in Dec. 2023 is calculated as:

Earnings Yield (Joel Greenblatt) % (Q: Dec. 2023 )	=	EBIT	/	Enterprise Value (Q: Dec. 2023 )
	=	853.09	/	10955.30254
	=	7.79 %

Dr Reddy's Laboratories's Enterprise Value for the quarter that ended in Dec. 2023 was $10,955 Mil.
Dr Reddy's Laboratories's EBIT for the trailing twelve months (TTM) ended in Dec. 2023 adds up the quarterly data reported by the company within the most recent 12 months, which was $853 Mil.

Dr Reddy's Laboratories EV-to-EBIT Related Terms

Thank you for viewing the detailed overview of Dr Reddy's Laboratories's EV-to-EBIT provided by GuruFocus.com. Please click on the following links to see related term pages.

Dr Reddy's Laboratories (Dr Reddy's Laboratories) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Dr Reddy's Laboratories Ltd (NYSE:RDY) » Definitions » EV-to-EBIT

Traded in Other Exchanges

DRREDDY:India 500124:India RDDA:Germany RDDA:Germany R1DY34:Brazil

Address

8-2-337, Road No. 3, Banjara Hills, Hyderabad, TG, IND, 500 034

Website

https://www.drreddys.com

Dr. Reddy's is one of the largest generic drug manufacturers in the world. It has a significant presence in North America, a region that makes up roughly half of its generics sales, and it services India (22% of its generics sales), Russia (12%), and certain European and Latin American countries. Beyond simple generics, Dr. Reddy's also has a solid portfolio of injectables which make up 25% of its North America sales. In branded generic markets like India, Dr. Reddy's has established a compelling presence with its strong brand name and earned a top five spot in key therapeutic areas including oncology and gastroenterology. Dr. Reddy's also has an active pharmaceutical ingredient business that manufactures over 150 APIs and sells in over 75 countries.